NYXH — Nyxoah SA Share News
0.000.00%
- €82.08m
- €52.26m
- €10.02m
Brief: Nyxoah Appoints John Landry As Chief Financial Officer
Brief: Nyxoah SA Says Appoints John Landry As CFO
Brief: Nyxoah Says FDA Regulatory Submission For Company's Genio® Device Is Complete, U.S. Approval On Track For End Of 2024
Brief: Nyxoah Announces Closing Of Pricing Offering
Brief: Nyxoah SA Sees Offering 5.4 Mln Of Ordinary Shares Pursuant To Prospectus Supplement
Brief: Nyxoah Shares Suspended Until Capital Increase By Accelerated Bookbuilding Is Published
Brief: Nyxoah Announces Reduction Of The Maximum Amount Available Under Its At The-Market Equity Offering Program
Brief: Nyxoah Says Co Announces Proposed Offering Of Ordinary Shares
Brief: Nyxoah Announces Dream U.S. Pivotal Study Meets Primary Endpoints
Brief: Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints
Brief: Nyxoah Q4 Operating Loss Widens To EUR 10.84 Million
Nyxoah SA reports results for the quarter ended in December - Earnings Summary
Brief: Nyxoah Announces 2024 Strategic Priorities
Brief: Nyxoah Announces Preliminary Results For The Fourth Quarter And Full Year 2023
Brief: Nyxoah: Real World Case Series Demonstrating Positive Results In Treating CCC Patients With Genio
Brief: Nyxoah Strengthens Its Executive Leadership Team
Brief: Nyxoah Announces Partnership With Resmed In Germany
Brief: Euronext Announces Quarterly Review Of BEL Family Indices
Brief: Nyxoah Appoints Christoph Eigenmann As Chief Commercial Officer